WVE
Wave Life Sciences Ltd. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | 0 | 83.58M | $485.57M | +8 | −9 |
| Q1 2026 | 91 | +3 | 75.16M | $544.65M | +10 | −7 |
| Q4 2025 | 87 | +2 | 83.62M | $1.42B | +4 | −2 |
| Q3 2025 | 17 | 0 | 51.40M | $376.26M | +2 | −3 |
| Q2 2025 | 15 | -1 | 44.33M | $288.15M | +1 | −2 |
| Q1 2025 | 13 | -1 | 25.22M | $203.80M | n/a | −1 |
| Q4 2024 | 14 | -1 | 25.08M | $310.31M | n/a | −1 |
| Q3 2024 | 14 | +2 | 20.71M | $169.87M | +2 | n/a |
| Q2 2024 | 12 | n/a | 14.01M | $69.91M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 5.36M | n/a | $26.74M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | PRIMECAP Management ✦ | 2.66M | n/a | $13.29M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.99M | n/a | $9.91M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 1.66M | n/a | $8.30M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.44M | n/a | $7.18M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Wellington Management ✦ | 428.31K | n/a | $2.14M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 7 | Two Sigma Investments ✦ | 124.68K | n/a | $622,148 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 115.48K | n/a | $576,235 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 108.57K | n/a | $541,749 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 62.10K | n/a | $309,890 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 33.53K | n/a | $167,310 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Citadel Advisors ✦ | 24.72K | n/a | $123,333 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 230 holders, 172.04M shares, $1.17B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 12.70K sh · $67,183
Director · 3.86K sh · $23,223
Director · 432 sh · $2,596
Director · 7.00K sh · $42,070
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
16.8% of class · View original SEC filing ↗